384 related articles for article (PubMed ID: 19004414)
1. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder.
Bouso JC; Doblin R; Farré M; Alcázar MA; Gómez-Jarabo G
J Psychoactive Drugs; 2008 Sep; 40(3):225-36. PubMed ID: 19004414
[TBL] [Abstract][Full Text] [Related]
2. 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.
Ot'alora G M; Grigsby J; Poulter B; Van Derveer JW; Giron SG; Jerome L; Feduccia AA; Hamilton S; Yazar-Klosinski B; Emerson A; Mithoefer MC; Doblin R
J Psychopharmacol; 2018 Dec; 32(12):1295-1307. PubMed ID: 30371148
[TBL] [Abstract][Full Text] [Related]
3. A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD).
Oehen P; Traber R; Widmer V; Schnyder U
J Psychopharmacol; 2013 Jan; 27(1):40-52. PubMed ID: 23118021
[TBL] [Abstract][Full Text] [Related]
4. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.
Mithoefer MC; Mithoefer AT; Feduccia AA; Jerome L; Wagner M; Wymer J; Holland J; Hamilton S; Yazar-Klosinski B; Emerson A; Doblin R
Lancet Psychiatry; 2018 Jun; 5(6):486-497. PubMed ID: 29728331
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Jerome L; Feduccia AA; Wang JB; Hamilton S; Yazar-Klosinski B; Emerson A; Mithoefer MC; Doblin R
Psychopharmacology (Berl); 2020 Aug; 237(8):2485-2497. PubMed ID: 32500209
[TBL] [Abstract][Full Text] [Related]
6. A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis.
Illingworth BJ; Lewis DJ; Lambarth AT; Stocking K; Duffy JM; Jelen LA; Rucker JJ
J Psychopharmacol; 2021 May; 35(5):501-511. PubMed ID: 33345689
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic investigation with MDMA (ecstasy)].
Bouso Saiz JC; Gómez-Jarabo G
Med Clin (Barc); 2003 Sep; 121(8):318; author reply 318-9. PubMed ID: 14499096
[No Abstract] [Full Text] [Related]
8. Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy.
Wagner MT; Mithoefer MC; Mithoefer AT; MacAulay RK; Jerome L; Yazar-Klosinski B; Doblin R
J Psychopharmacol; 2017 Aug; 31(8):967-974. PubMed ID: 28635375
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD.
Marseille E; Kahn JG; Yazar-Klosinski B; Doblin R
PLoS One; 2020; 15(10):e0239997. PubMed ID: 33052965
[TBL] [Abstract][Full Text] [Related]
10. MDMA-assisted psychotherapy for posttraumatic stress disorder: A promising novel approach to treatment.
Vermetten E; Yehuda R
Neuropsychopharmacology; 2020 Jan; 45(1):231-232. PubMed ID: 31455855
[No Abstract] [Full Text] [Related]
11. Perceived Benefits of MDMA-Assisted Psychotherapy beyond Symptom Reduction: Qualitative Follow-Up Study of a Clinical Trial for Individuals with Treatment-Resistant PTSD.
Barone W; Beck J; Mitsunaga-Whitten M; Perl P
J Psychoactive Drugs; 2019; 51(2):199-208. PubMed ID: 30849288
[TBL] [Abstract][Full Text] [Related]
12. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Mithoefer MC; Feduccia AA; Jerome L; Mithoefer A; Wagner M; Walsh Z; Hamilton S; Yazar-Klosinski B; Emerson A; Doblin R
Psychopharmacology (Berl); 2019 Sep; 236(9):2735-2745. PubMed ID: 31065731
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis.
Bahji A; Forsyth A; Groll D; Hawken ER
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jan; 96():109735. PubMed ID: 31437480
[TBL] [Abstract][Full Text] [Related]
14. Potential Psychiatric Uses for MDMA.
Yazar-Klosinski BB; Mithoefer MC
Clin Pharmacol Ther; 2017 Feb; 101(2):194-196. PubMed ID: 27859039
[TBL] [Abstract][Full Text] [Related]
15. Acute subjective effects in LSD- and MDMA-assisted psychotherapy.
Schmid Y; Gasser P; Oehen P; Liechti ME
J Psychopharmacol; 2021 Apr; 35(4):362-374. PubMed ID: 33853422
[TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.
Mithoefer MC; Wagner MT; Mithoefer AT; Jerome L; Doblin R
J Psychopharmacol; 2011 Apr; 25(4):439-52. PubMed ID: 20643699
[TBL] [Abstract][Full Text] [Related]
17. Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder.
Zeifman RJ; Kettner H; Ross S; Weiss B; Mithoefer MC; Mithoefer AT; Wagner AC
Eur J Psychotraumatol; 2024; 15(1):2297536. PubMed ID: 38174611
[TBL] [Abstract][Full Text] [Related]
18. Is there a case for MDMA-assisted psychotherapy in the UK?
Sessa B
J Psychopharmacol; 2007 Mar; 21(2):220-4. PubMed ID: 17329304
[TBL] [Abstract][Full Text] [Related]
19. The Psychopharmacology of ±3,4 Methylenedioxymethamphetamine and its Role in the Treatment of Posttraumatic Stress Disorder.
Amoroso T
J Psychoactive Drugs; 2015; 47(5):337-44. PubMed ID: 26579955
[TBL] [Abstract][Full Text] [Related]
20. Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder.
Gorman I; Belser AB; Jerome L; Hennigan C; Shechet B; Hamilton S; Yazar-Klosinski B; Emerson A; Feduccia AA
J Trauma Stress; 2020 Apr; 33(2):161-170. PubMed ID: 32073177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
